10-Q: Nordicus Partners Reports Q1 Loss Amid R&D Progress

Nordicus Partners Corporation reported a significant increase in net loss for the quarter ended June 30, 2025, driven by higher operating expenses and investment losses, despite positive preclinical developments for its portfolio companies.

Summary

• Net loss for the three months ended June 30, 2025, increased to $1,206,886 from $258,169 in the prior year period.
• Total operating expenses rose to $831,886 from $258,169, primarily due to increased professional fees and new research and development costs.
• Cash balance decreased to $8,418 as of June 30, 2025, from $19,914 as of March 31, 2025.
• The company recognized a $375,000 loss on the fair value of its investment in Mag Mile Capital, Inc.
• A significant foreign currency translation gain of $5,192,630 contributed to a positive comprehensive income of $3,985,744.
• Orocidin A/S successfully completed a 14-day toxicology study in hamsters and a Beagle Dog Study, showing high tolerance and direct effect on periodontitis.
• Bio-Convert A/S received positive scientific advice from the Danish Medicines Agency, potentially allowing a First in Human trial without further animal studies.
• The company issued 89,000 shares of common stock to private investors for $409,970 during the quarter.
• Subsequent to the quarter, 525,013 restricted shares were issued to private investors for $997,525.
• The Board of Directors expanded from three to five members, with three new directors appointed on August 7, 2025.

Sentiment

Score: 3

Explanation: While there are positive preclinical developments for Orocidin and Bio-Convert, the significant increase in net loss, substantial cash burn, explicit going concern warning, and ineffective internal controls present major financial challenges and risks. The positive foreign currency translation is a non-operating gain and does not offset the underlying operational issues. The capital raises are necessary but also highlight the ongoing need for external funding.

Positives

• Orocidin A/S successfully completed a 14-day toxicology study in hamsters, demonstrating high tolerance and no adverse reactions.
• Orocidin A/S's Beagle Dog Study showed QR-01 had a direct effect on periodontitis, with consistent improvements in key clinical endpoints and good tolerability.
• Bio-Convert A/S received positive and constructive scientific advice from the Danish Medicines Agency, indicating a high likelihood of proceeding to a First in Human trial without additional animal studies.
• Innovative oral formulations used by Orocidin and Bio-Convert ensure prolonged adhesion for 12-24 hours and controlled release, enhancing drug efficacy.
• A significant foreign currency translation adjustment resulted in a gain of $5,192,630 for the three months ended June 30, 2025.
• Net loss per share decreased to $(0.07) from $(0.08) despite a higher net loss, due to a substantial increase in weighted average common shares outstanding.

Negatives

• Net loss significantly increased to $1,206,886 for the three months ended June 30, 2025, compared to $258,169 for the same period in 2024.
• Total operating expenses surged by 222% to $831,886, driven by a 977% increase in professional fees and new research and development expenses.
• Cash balance declined to $8,418 as of June 30, 2025, from $19,914 as of March 31, 2025, indicating continued cash burn.
• A $375,000 loss was recorded on the change in fair value of the investment in Mag Mile Capital, Inc.
• The company has recognized nominal revenue and incurred losses since inception, resulting in an accumulated deficit of $47,991,734.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025, due to limited resources in the finance and accounting functions.

Risks

• Substantial doubt about the ability to continue as a going concern due to nominal revenue, an accumulated deficit of $47,991,734, and a cash balance of $8,418 as of June 30, 2025.
• Current funds are insufficient to meet needs for more than twelve months from the date of issuance of the financial statements.
• Disclosure controls and procedures were not effective as of June 30, 2025, due to limited resources in the finance and accounting functions.
• Operations are subject to factors such as the results of research and development, clinical testing, regulatory approval, competition, product demand and pricing, ability to negotiate licensing agreements, and ability to raise capital.
• The fair value of performance awards is variable and dependent on future events, making compensation expense recognition uncertain.
• The company maintains cash in foreign bank accounts that are not federally insured, exposing it to credit risk.

Future Outlook

Management intends to finance operating costs over the next twelve months with existing cash on hand and through private placements of Common Stock. The company aims to take all portfolio companies' drug developments through Phase I, after which options include sale/merger, further clinical development, strategic partnerships, or a stand-alone IPO.

Management Comments

• Management intends to finance operating costs over the next twelve months with existing cash on hand and through private placements of Common Stock.
• The Company endeavors to create a distinct advantage in identifying, scaling, and exiting high-potential companies in fast-growing markets with unmet medical needs.
• Nordicus mission is to back high-growth ventures and transformative innovations in the life sciences sector.
• Nordicus portfolio diversification strategy aims to positions it as a stable and resilient company, mitigating risk with significant upside potential.
• The companies innovative breakthroughs are further strengthened by their oral formulations ensuring prolonged adhesion for 12-24 hours and controlled release of the active ingredient, enhancing drug efficacy and patients outcomes – a major advancement over normal gels and creams.
• The successful completion of this study marks an important milestone for Orocidin A/S, providing the foundation for the upcoming pivotal 8-week toxicity study.
• This represents a significant milestone for Orocidin’s lead product, QR-01, and strengthens Nordicus and Orocidin’s confidence as Orocidin prepare for the upcoming human pilot efficacy study.
• DKMA’s feedback paves the way toward a First in Human trial, with a high likelihood of animal studies rendered dispensable for the proposed formulation and route of application.

Industry Context

Nordicus Partners operates as a business accelerator and holding company focused on bridging Nordic life sciences innovation with the American market. This strategy taps into the growing global demand for novel biotechnological solutions, particularly in areas like oral health where unmet medical needs persist. The company's focus on preclinical-stage assets like Orocidin A/S (periodontitis) and Bio-Convert A/S (oral leukoplakia) aligns with a trend of early-stage investment in high-potential therapeutic areas. The emphasis on proprietary mucoadhesive oral topical formulations represents an advancement in drug delivery within the oral care segment, potentially offering improved patient outcomes compared to traditional methods.

Management Changes

Corporate Governance

Legal Proceedings

• Not the subject of any pending legal proceedings, and no proceedings are presently contemplated against the company by any federal, state, or local governmental agency. No director or executive officer is party to any action with an adverse interest to the company.

Related Party Transactions

• GK Partners purchased 49,000 shares of common stock for $245,000 during the three months ended June 30, 2025.
• Legal fees to an affiliate of Mr. Bennett Yankowitz (CFO and director) were $294 for the three months ended June 30, 2025, a significant decrease from $17,782 in the prior year period.
• Henrik Rouf's (CEO) annual salary was increased to $360,000, effective July 1, 2025, and his term extended to July 1, 2026.
• Bennett Yankowitz's (CFO and director) annual salary was increased to $120,000, effective July 1, 2025, and his term extended to July 1, 2026.
• A related party forgave a payable of $13,886 during the three months ended June 30, 2024, which was credited to additional paid-in capital.

Stakeholder Impact

• Shareholders: Experience significant net losses and dilution from ongoing stock issuances for capital raises. The going concern warning poses a substantial risk to investment value. Positive preclinical results offer potential long-term upside, but are offset by immediate financial challenges.
• Employees/Management: CEO and CFO salaries increased, indicating continued investment in leadership, but the overall financial health and going concern risk could impact employee morale and retention.
• Customers/Partners: The company's focus on advancing preclinical biotechnology products (Orocidin and Bio-Convert) could lead to future innovative treatments, benefiting potential patients and healthcare providers.
• Creditors: The 'going concern' warning and low cash balance indicate elevated risk for current and potential creditors.

Next Steps

• Orocidin A/S to conduct an upcoming pivotal 8-week toxicity study.
• Orocidin A/S to prepare for an upcoming human pilot efficacy study.
• Bio-Convert A/S to proceed towards a First in Human trial for QR-02.
• Management intends to finance operating costs over the next twelve months with existing cash on hand and through private placements of Common Stock.
• The company will reassess the probability of achievement for performance awards at each reporting date and recognize compensation expense if and when the performance condition becomes probable.
• The company intends to take appropriate and reasonable steps to make improvements to remediate deficiencies in disclosure controls and procedures.
• The company anticipates reflecting the impact of ASU 2023-09 in its annual financial statements for the year ended March 31, 2026.
• The company is evaluating the impact of ASU 2024-03 and ASU 2025-01 on its financial statements.
• Nordicus aims to take all portfolio companies' drug developments through Phase I.
• Upon completion of Phase I, options include sale/merger of the portfolio company, further development through next clinical phases, strategic partnership with a large pharmaceutical company, or a stand-alone Initial Public Offering (IPO).

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial increase in net loss, significant cash burn, and an explicit 'going concern' warning. While there are promising preclinical developments for its portfolio companies, these are early-stage and do not mitigate the immediate liquidity and operational risks. The ineffective internal controls further compound governance concerns. Despite recent capital raises, the company's ability to sustain operations and fund future development is highly questionable. A seasoned investor would likely view the current financial position as unsustainable without significant, immediate, and successful capital infusion, making the stock a high-risk 'sell' at this juncture.

Keywords

Nordicus Partners, NORD, SEC Filing, 10-Q, Biotechnology, Life Sciences, Oral Health, Orocidin A/S, Bio-Convert A/S, Periodontitis, Oral Leukoplakia, Preclinical Stage, Drug Development, Financial Results, Going Concern, Research and Development, Corporate Governance, Stock Options, Capital Raise